The UK’s medicines regulator on Thursday approved an antibody treatment for COVID-19, the disease caused by the CCP virus. Xevudy (sotrovimab), developed by GlaxoSmithKline (GSK) and Vir Biotechnology, is the second monoclonal antibody treatment approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) after it approved Lagevrio (molnupiravir) last month. The drug is administered by intravenous infusion…